Asset

  • No.

    96

  • Asset Title

    α-synuclein inhibitor_Neurodegenerative Disorders

  • Organization

    University of California, San Diego

  • Product Type

    Small molecule

  • Therapeutic Area

    Neurology, CNS disease

  • Development Stage

    Hit To Lead or Lead Optimization

  • Technical Summary

    Researchers at UC San Diego have developed a novel strategy to treat PD by using small molecules interacting with native α-Syn that could protect and stabilize specific conformations present in the ensemble, which in turn could provide protective action.  A compound has been identified that displayed protective activity in preventing the transmission of α-Syn from cell to cell thus supporting the notion that small molecules can target an intrinsically disordered protein such as α-Syn. This compound does not directly affect the process of α-Syn misfolding or aggregation and thus offers a novel mode-of-action beyond previously described aggregation blockers.

  • Researcher

  • Patent

  • Publication

  • Attachment

TOP